The latest price reference for Erdafitinib in 2025

Erdafitinib (Erdafitinib) is an oral small molecule targeted drug, mainly used to treat advanced bladder cancer with FGFR gene abnormalities. Its mechanism of action is to selectively inhibit the activity of fibroblast growth factor receptor (FGFR), thereby blocking cancer cell proliferation and angiogenesis signals. This type of targeted drug is particularly suitable for patients with bladder cancer, especially those whose disease has progressed despite previous chemotherapy or immunotherapy. By precisely intervening in tumor molecular abnormalities, erdafitinib can delay disease progression, improve patients' quality of life to a certain extent, and provide new treatment opportunities for patients who have failed standard treatments.

In the domestic market, erdafitinib has been officially launched. Common specifications include3mg 56 tablets, 4mg 28 tablets and 5mg*28 tablets. However, since the drug has not yet been included in medical insurance, the direct purchase cost is high. In terms of price, each box of medicine costs approximately several thousand to tens of thousands of yuan, and the specific price varies depending on specifications and procurement channels. In overseas markets, the original drugs are mainly the Hong Kong version, priced at more than 20,000 yuan, and need to be purchased through regular Hong Kong pharmacy channels. At the same time, there are a variety of generic drugs overseas, such as the Lao version and the Bangladeshi Yaopin International version. These generic drugs are basically the same as the original drugs in terms of pharmaceutical ingredients, but the price is significantly lower than the original drugs, usually between a few hundred to more than 2,000 yuan, providing patients with an economically feasible alternative.

When choosing a purchasing channel, patients need to pay attention to the legality and quality assurance of the drugs, and ensure that the drugs they use come from regular sources. Clinically, doctors will develop an individualized treatment plan based on the patient's condition, type of FGFR abnormality and tolerance, and monitor renal function, electrolyte levels and other potential side effects. Scientific and reasonable medication management can help reduce treatment risks and economic burden while ensuring therapeutic efficacy.

In general, erdafitinib is mainly used to treat advanced bladder cancer and a few other solid tumors related to FGFR abnormalities. Its precise targeting mechanism gives it advantages in improving disease control and quality of life.

Reference materials：https://www.balversa.com/